A detailed history of Johnson Investment Counsel Inc transactions in Cassava Sciences Inc stock. As of the latest transaction made, Johnson Investment Counsel Inc holds 7,000 shares of SAVA stock, worth $182,980. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,000
Holding current value
$182,980
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$9.57 - $35.08 $66,990 - $245,560
7,000 New
7,000 $206,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $1.05B
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Johnson Investment Counsel Inc Portfolio

Follow Johnson Investment Counsel Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Johnson Investment Counsel Inc, based on Form 13F filings with the SEC.

News

Stay updated on Johnson Investment Counsel Inc with notifications on news.